Pharsight

1. List of Ongentys drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8907099	NEUROCRINE	Nitrocatechol derivatives as COMT inhibitors	May, 2027 (4 years from now)
US8168793	NEUROCRINE	Nitrocatechol derivatives as COMT inhibitors	Apr, 2029 (6 years from now)
US9630955	NEUROCRINE	Chemical compound useful as intermediate for preparing a catechol-O-methyltransferase inhibitor	Dec, 2032 (9 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9550759	NEUROCRINE	Nitrocatechol derivatives as COMT inhibitors	Jul, 2026 (3 years from now)
US9745290	NEUROCRINE	Dosage regimen for COMT inhibitors	Oct, 2027 (4 years from now)
US8524746	NEUROCRINE	Dosage regimen for COMT inhibitors	Jul, 2029 (6 years from now)
US10071085	NEUROCRINE	Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof	Mar, 2030 (7 years from now)
US10583130	NEUROCRINE	Pharmaceutical formulations compromising nitrocatechol derivatives and methods of making thereof	Mar, 2030 (7 years from now)
US10357468	NEUROCRINE	Medicaments for slowing Parkinson's disease	May, 2035 (12 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Apr 24, 2025

NCE-1 date: April, 2024

Market Authorisation Date: 24 April, 2020

Treatment: Method of inhibiting comt in the periphery; Method of treating parkinson's disease; Method of reducing o-methylation of l-dopa; Adjunctive treatment to levodopa/carbidopa in patients with parkinson's disease

Dosage: CAPSULE;ORAL